期刊文献+

嗜酸性粒细胞增多综合征的临床特征及诊疗进展 被引量:3

下载PDF
导出
摘要 嗜酸性粒细胞增多综合征(hypereosinophilic syndrome , H ES )是一组病因不明,以血液和(或)骨髓嗜酸性粒细胞持续增多,伴有组织中嗜酸性粒细胞大量浸润为特征的疾病。1975年Chusid等[1]提出 HES的诊断标准:(1)外周血中嗜酸性粒细胞计数大于1.5×10 9/L ,并持续6个月以上;(2)排除导致嗜酸性粒细胞增多的其他原因,如寄生虫感染、过敏性疾病、血管炎或肿瘤等;(3)出现多系统、多器官损害的表现。近年来随着发病机制的研究,越来越多的H ES亚类被独立出来,各个亚类临床特征有所不同,本文主要就 H ES不同亚类的特点及治疗进展作一综述。
出处 《重庆医学》 CAS CSCD 北大核心 2014年第21期2818-2820,共3页 Chongqing medicine
  • 相关文献

参考文献25

  • 1Chusid M J, Dale DC, West BC, et al. The hypereosinophil- ic syndrome : analysis of fourteen cases with review of the literature[J]. Medicine(Baltimore), 1975,54 ( 1 ) : 1-27.
  • 2Ogbogu PU, Bochner BS, Butterfield J H, et al. Hypereosi- nophilic syndrome : a multicenter, retrospective analysis of clinical characteristics and response to therapy[J]. J Al- lergy Clin Immunol,2009,124(6):1319-1325.
  • 3Sheikh J ,Weller PF. Clinical overview of hypereosinophil ic syndromes[J]. Immunol All Clin N Am, 2007,27(3) : 333-355.
  • 4Baccarani M,Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha- positive hypereosinophilic syndrome. Results of a multi- center prospective study[J]. Haematologica, 2007,92 (9) : 1173-1179.
  • 5Helbig G,Stella-Holowiecka B, Majewski M,et al. A sin- gle weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIPIL1-PDGFRA expressing patients[J]. Br J Haematol, 2008,141 (2) : 200-204.
  • 6yon Bubnoff N, Gorantla SP, Engh RA,et al. The low fre- quency of clinical resistance to PDGFR inhibitors in mye- loid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA ki- nase domain mutations in vitro[J]. Oncogene, 2011, 30 (8) :933-943.
  • 7Tabouret E,Charbonnier A, Mozzieonacci MJ, et al. Low- dose nilotinib can maintain complete molecular remission in FIP1L1/PDGFRA-positive hypereosinophilic syndrome [J]. Leuk Res,2011,35(1) :136.
  • 8Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilie syndrome [J]. Blood, 2004,103 (2) : 473-478.
  • 9Butterfield JH. Success of short-term, higher-dose ima- tinib mesylate to induce clinical response in FIP1L1-PDG- FRalpha-negative hypereosinophilic syndrome [J]. Leuk Res, 2009,33(8). 1127-1129.
  • 10Hans U,Amy K. Therapeutic approaches to patients with hypereosinophilic syndromes[J]. Semin Hematol, 2012, 49 (2): 160-170.

同被引文献25

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部